Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study

JAMI investigators

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). METHODS: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. RESULTS: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation-associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). CONCLUSION: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.

Original languageEnglish
Pages (from-to)112-119
Number of pages8
JournalRheumatology (Oxford, England)
Volume59
Issue number1
DOIs
Publication statusPublished - 2020 Jan 1

Fingerprint

Myositis
Interstitial Lung Diseases
Multicenter Studies
Cohort Studies
Neoplasms
Arthritis
Mortality
Amino Acyl-tRNA Synthetases
Survival Analysis
Serum
Respiratory Insufficiency
Autoantibodies
Melanoma
Demography

Keywords

  • cancer-associated
  • interstitial lung diseases
  • myositis

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease : a large-scale multicentre cohort study. / JAMI investigators .

In: Rheumatology (Oxford, England), Vol. 59, No. 1, 01.01.2020, p. 112-119.

Research output: Contribution to journalArticle

@article{85564e8560a74b1696aabccc28f887d6,
title = "Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study",
abstract = "OBJECTIVE: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). METHODS: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. RESULTS: CAM was identified in 32 patients with PM/DM-associated ILD (6.4{\%}). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24{\%} vs 49{\%}, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation-associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). CONCLUSION: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.",
keywords = "cancer-associated, interstitial lung diseases, myositis",
author = "{JAMI investigators} and Yuko Kaneko and Takahiro Nunokawa and Yoshinori Taniguchi and Yukie Yamaguchi and Takahisa Gono and Kenichi Masui and Atsushi Kawakami and Yasushi Kawaguchi and Shinji Sato and Masataka Kuwana",
year = "2020",
month = "1",
day = "1",
doi = "10.1093/rheumatology/kez238",
language = "English",
volume = "59",
pages = "112--119",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease

T2 - a large-scale multicentre cohort study

AU - JAMI investigators

AU - Kaneko, Yuko

AU - Nunokawa, Takahiro

AU - Taniguchi, Yoshinori

AU - Yamaguchi, Yukie

AU - Gono, Takahisa

AU - Masui, Kenichi

AU - Kawakami, Atsushi

AU - Kawaguchi, Yasushi

AU - Sato, Shinji

AU - Kuwana, Masataka

PY - 2020/1/1

Y1 - 2020/1/1

N2 - OBJECTIVE: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). METHODS: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. RESULTS: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation-associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). CONCLUSION: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.

AB - OBJECTIVE: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). METHODS: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. RESULTS: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation-associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). CONCLUSION: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.

KW - cancer-associated

KW - interstitial lung diseases

KW - myositis

UR - http://www.scopus.com/inward/record.url?scp=85076448504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076448504&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kez238

DO - 10.1093/rheumatology/kez238

M3 - Article

C2 - 31382295

AN - SCOPUS:85076448504

VL - 59

SP - 112

EP - 119

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 1

ER -